Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hypertension
Volume 2011, Article ID 495349, 10 pages
http://dx.doi.org/10.4061/2011/495349
Review Article

Left Ventricular Hypertrophy: Major Risk Factor in Patients with Hypertension: Update and Practical Clinical Applications

Prairie Cardiovascular Consultants, Ltd., 619 E. Mason Street, Ste. 4P57, Springfield, IL 62701, USA

Received 15 February 2011; Accepted 19 April 2011

Academic Editor: Amgad N. Makaryus

Copyright © 2011 Richard E. Katholi and Daniel M. Couri. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Sagie, E. J. Benjamin, M. Galderisi et al., “Echocardiographic assessment of left ventricular structure and diastolic filling in elderly subjects with borderline isolated systolic hypertension (the Framingham Heart Study),” American Journal of Cardiology, vol. 72, no. 9, pp. 662–665, 1993. View at Publisher · View at Google Scholar · View at Scopus
  2. W. S. Post, M. G. Larson, and D. Levy, “Impact of left ventricular structure on the incidence of hypertension: the Framingham Heart Study,” Circulation, vol. 90, no. 1, pp. 179–185, 1994. View at Google Scholar · View at Scopus
  3. P. Anversa, E. Puntillo, G. Olivetti et al., “Cellular and mechanical adaptations in cardiac hypertrophy and its reversal,” Cardiovascular Reviews and Reports, vol. 11, no. 12, pp. 34–41, 1990. View at Google Scholar
  4. D. B. Johnson and L. J. Dell'Italia, “Cardiac hypertrophy and failure in hypertension,” Current Opinion in Nephrology and Hypertension, vol. 5, no. 2, pp. 186–191, 1996. View at Publisher · View at Google Scholar · View at Scopus
  5. T. E. Simpson, H. M. Dansky, and P. M. Buttrick, “Molecular genetic mechanisms of cardiac hypertrophy,” Cardiovascular Risk Factors, vol. 5, no. 2, pp. 93–108, 1995. View at Google Scholar · View at Scopus
  6. M. Moser, “Initial workup of the hypertensive patient,” in Hypertensive Primer: The Essentials of High Blood Pressure, J. L. Izzo, H. R. Black, and T. L. Goodfriend, Eds., pp. 221–223, Williams and Wilkins, Philadelphia, Pa, USA, 1998. View at Google Scholar
  7. W. B. Kannel, “Prevalence and natural history of electrocardiographic left ventricular hypertrophy,” American Journal of Medicine, vol. 75, no. 3 A, pp. 4–11, 1983. View at Google Scholar · View at Scopus
  8. P. N. Casale, R. B. Devereux, and M. Milner, “Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men,” Annals of Internal Medicine, vol. 105, no. 2, pp. 173–178, 1986. View at Google Scholar · View at Scopus
  9. Y. Sugishita, K. Iida, K. Fujieda, and K. Yukisada, “Decreased adrenergic response in hypertensive patients without left ventricular hypertrophy,” Clinical Cardiology, vol. 17, no. 2, pp. 71–76, 1994. View at Google Scholar · View at Scopus
  10. R. E. Katholi, M. R. Ervin, and G. Ginsburg, “Hypertensive heart disease syndrome in women in a cardiology practice,” Comprehensive Therapy, vol. 23, no. 8, pp. 508–513, 1997. View at Google Scholar · View at Scopus
  11. Y. Liao, R. S. Cooper, G. A. Mensah, and D. L. McGee, “Left ventricular hypertrophy has a greater impact on survival in women than in men,” Circulation, vol. 92, no. 4, pp. 805–810, 1995. View at Google Scholar · View at Scopus
  12. S. Wassertheil-Smoller, B. Psaty, P. Greenland et al., “Association between cardiovascular outcomes and antihypertensive drug treatment in older women,” Journal of the American Medical Association, vol. 292, no. 23, pp. 2849–2859, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. J. S. Mogil, W. F. Sternberg, B. Kest, P. Marek, and J. C. Liebeskind, “Sex differences in the antagonism of swim stress-induced analgesia: effects of gonadectomy and estrogen replacement,” Pain, vol. 53, no. 1, pp. 17–25, 1993. View at Publisher · View at Google Scholar · View at Scopus
  14. G. M. C. Rosano, N. S. Peters, D. Lefroy et al., “17-beta-estradiol therapy lessens angina in postmenopausal women with syndrome X,” Journal of the American College of Cardiology, vol. 28, no. 6, pp. 1500–1505, 1996. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Mulé, E. Nardi, S. Cottone et al., “Impact of the metabolic syndrome on total arterial compliance in essential hypertension patients,” Journal of the Cardiometabolic Syndrome, vol. 2, no. 2, pp. 84–90, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Verdecchia, G. Schillaci, M. Guerrieri et al., “Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension,” Circulation, vol. 81, no. 2, pp. 528–536, 1990. View at Google Scholar · View at Scopus
  17. A. Sharp, R. Tapp, D. P. Francis et al., “Ethnicity and left ventricular diastolic function in hypertension an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy,” Journal of the American College of Cardiology, vol. 52, no. 12, pp. 1015–1021, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. A. M. Grandi, R. Broggi, S. Colombo et al., “Left ventricular changes in isolated office hypertension: a blood pressure-matched comparison with normotension and sustained hypertension,” Archives of Internal Medicine, vol. 161, no. 22, pp. 2677–2681, 2001. View at Google Scholar · View at Scopus
  19. A. Losito, R. M. Fagugli, I. Zampi et al., “Comparison of target organ damage in renovascular and essential hypertension,” American Journal of Hypertension, vol. 9, no. 11, pp. 1062–1067, 1996. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Wu, N. Polavarapu, and G. A. Stouffer, “Left ventricular hypertrophy in patients with renal artery stenosis,” American Journal of the Medical Sciences, vol. 332, no. 6, pp. 334–338, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. G. P. Rossi, A. Sacchetto, E. Pavan et al., “Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma,” Circulation, vol. 95, no. 6, pp. 1471–1478, 1997. View at Google Scholar · View at Scopus
  22. W. H. Frishman, “Diagnosis and treatment of systolic heart failure in the elderly,” American Journal of Geriatric Cardiology, vol. 7, no. 6, pp. 10–55, 1998. View at Google Scholar · View at Scopus
  23. R. N. Foley, P. S. Parfrey, J. D. Harnett, G. M. Kent, D. C. Murray, and P. E. Barre, “Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease,” Kidney International, vol. 49, no. 5, pp. 1379–1385, 1996. View at Google Scholar · View at Scopus
  24. R. E. Katholi, “Left ventricular hypertrophy: strategies for prevention and regression,” Midwest Health, vol. 2, pp. 26–32, 2000. View at Google Scholar
  25. G. W. Ching, J. A. Franklyn, T. J. Stallard, J. Daykin, M. C. Sheppard, and M. D. Gammage, “Cardiac hypertrophy as a result of long-term thyroxine therapy and thyrotoxicosis,” Heart, vol. 75, no. 4, pp. 363–368, 1996. View at Google Scholar · View at Scopus
  26. J. P. Singh, J. Johnston, P. Sleight, R. Bird, K. Ryder, and G. Hart, “Left ventricular hypertrophy in hypertensive patients is associated with abnormal rate adaptation of QT interval,” Journal of the American College of Cardiology, vol. 29, no. 4, pp. 778–784, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. B. J. Maron, A. Pelliccia, and P. Spirito, “Cardiac disease in young trained athletes: insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy,” Circulation, vol. 91, no. 5, pp. 1596–1601, 1995. View at Google Scholar · View at Scopus
  28. B. J. Maron, “Sudden death in young athletes,” New England Journal of Medicine, vol. 349, no. 11, pp. 1064–1075, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. R. B. Devereux and N. Reichek, “Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method,” Circulation, vol. 55, no. 4, pp. 613–618, 1977. View at Google Scholar · View at Scopus
  30. P. S. Douglas, M. L. O'Toole, S. E. Katz, G. S. Ginsburg, W. D. B. Hiller, and R. H. Laird, “Left ventricular hypertrophy in athletes,” American Journal of Cardiology, vol. 80, no. 10, pp. 1384–1388, 1997. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Pelliccia, F. Culasso, F. M. Di Paolo, and B. J. Maron, “Physiologic left ventricular cavity dilatation in elite athletes,” Annals of Internal Medicine, vol. 130, no. 1, pp. 23–31, 1999. View at Google Scholar · View at Scopus
  32. N. Reichek, J. Helak, and T. Plappert, “Anatomic validation of left ventricular mass estimates from clinical two-dimensional echocardiography: initial results,” Circulation, vol. 67, no. 2, pp. 348–352, 1983. View at Google Scholar · View at Scopus
  33. S. G. Myerson, N. G. Bellenger, and D. J. Pennell, “Assessment of left ventricular mass by cardiovascular magnetic resonance,” Hypertension, vol. 39, no. 3, pp. 750–755, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. J. C. C. Moon, N. G. Fisher, W. J. McKenna, and D. J. Pennell, “Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography,” Heart, vol. 90, no. 6, pp. 645–649, 2004. View at Google Scholar · View at Scopus
  35. I. Olivotto, B. J. Maron, E. Appelbaum et al., “Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy,” American Journal of Cardiology, vol. 106, no. 2, pp. 261–267, 2010. View at Publisher · View at Google Scholar · View at PubMed
  36. V. O. Puntmann, C. Jahnke, R. Gebker et al., “Usefulness of magnetic resonance imaging to distinguish hypertensive and hypertrophic cardiomyopathy,” American Journal of Cardiology, vol. 106, no. 7, pp. 1016–1022, 2010. View at Publisher · View at Google Scholar · View at PubMed
  37. M. L. Muiesan, M. Salvetti, D. Rizzoni, M. Castellano, F. Donato, and E. Agabiti-Rosei, “Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment,” Journal of Hypertension, vol. 13, no. 10, pp. 1091–1095, 1995. View at Publisher · View at Google Scholar · View at Scopus
  38. R. B. Devereux, E. Agabiti-Rosei, B. Dahlof et al., “Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials,” Journal of Hypertension, Supplement, vol. 14, no. 2, pp. S95–S102, 1996. View at Google Scholar
  39. R. B. Devereux, K. Wachtell, E. Gerdts et al., “Prognostic significance of left ventricular mass change during treatment of hypertension,” Journal of the American Medical Association, vol. 292, no. 19, pp. 2350–2356, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. P. M. Okin, R. B. Devereux, S. Jern et al., “Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events,” Journal of the American Medical Association, vol. 292, no. 19, pp. 2343–2349, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. P. M. Okin, R. B. Devereux, K. E. Harris et al., “Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients,” Annals of Internal Medicine, vol. 147, no. 5, pp. 311–319, 2007. View at Google Scholar · View at Scopus
  42. K. Wachtell, P. M. Okin, M. H. Olsen et al., “Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE study,” Circulation, vol. 116, no. 7, pp. 700–705, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. L. A. Ferrara, G. De Simone, F. Pasanisi, and M. Mancini, “Left ventricular mass reduction during salt depletion in arterial hypertension,” Hypertension, vol. 6, no. 5, pp. 755–759, 1984. View at Google Scholar · View at Scopus
  44. B. Arroll and R. Beaglehole, “Does physical activity lower blood pressure: a critical review of the clinical trials,” Journal of Clinical Epidemiology, vol. 45, no. 5, pp. 439–447, 1992. View at Publisher · View at Google Scholar · View at Scopus
  45. H. F. Becker, A. Jerrentrup, T. Ploch et al., “Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea,” Circulation, vol. 107, no. 1, pp. 68–73, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. R. E. Schmieder, P. Martus, and A. Klingbeil, “Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies,” Journal of the American Medical Association, vol. 275, no. 19, pp. 1507–1513, 1996. View at Publisher · View at Google Scholar · View at Scopus
  47. P. R. Liebson, G. A. Grandits, S. Dianzumba et al., “Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study (TOMHS),” Circulation, vol. 91, no. 3, pp. 698–706, 1995. View at Google Scholar · View at Scopus
  48. J. S. Gottdiener, D. J. Reda, B. M. Massie, B. J. Materson, D. W. Williams, and R. J. Anderson, “Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents,” Circulation, vol. 95, no. 8, pp. 2007–2014, 1997. View at Google Scholar
  49. R. J. Tapp, A. Sharp, A. V. Stanton et al., “Differential effects of antihypertensive treatment on left ventricular diastolic function: an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy,” Journal of the American College of Cardiology, vol. 55, no. 17, pp. 1875–1881, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. M. Iriarte, R. Caso, N. Murga et al., “Enalapril-induced regression of hypertensive left ventricular hypertrophy, regional ischemia, and microvascular angina,” American Journal of Cardiology, vol. 75, no. 12, pp. 850–852, 1995. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Mathew, P. Sleight, E. Lonn et al., “Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril,” Circulation, vol. 104, no. 14, pp. 1615–1621, 2001. View at Google Scholar · View at Scopus
  52. S. D. Solomon, E. Appelbaum, W. J. Manning et al., “Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy,” Circulation, vol. 119, no. 4, pp. 530–537, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. X. Zhang, Y. W. Xie, A. Nasjletti, X. Xu, M. S. Wolin, and T. H. Hintze, “ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption,” Circulation, vol. 95, no. 1, pp. 176–182, 1997. View at Google Scholar · View at Scopus
  54. S. E. Nissen, E. M. Tuzcu, P. Libby et al., “Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial,” Journal of the American Medical Association, vol. 292, no. 18, pp. 2217–2226, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. W. H. Frishman, A. E. Skolnick, and J. A. Strom, “Effects of calcium entry blockade on hypertension-induced left ventricular hypertrophy,” Circulation, vol. 80, no. 6, pp. IV151–IV161, 1989. View at Google Scholar · View at Scopus
  56. M. Vogt and B. E. Strauer, “Response of hypertensive left ventricular hypertrophy and coronary microvascular disease to calcium antagonists,” American Journal of Cardiology, vol. 76, no. 13, pp. 24D–30D, 1995. View at Publisher · View at Google Scholar · View at Scopus
  57. F. C. Barone, W. G. Campbell Jr., A. H. Nelson, and G. Z. Feuerstein, “Carvedilol prevents severe hypertensive cardiomyopathy and remodeling,” Journal of Hypertension, vol. 16, no. 6, pp. 871–884, 1998. View at Publisher · View at Google Scholar · View at Scopus
  58. L. Hansson and A. Himmelmann, “Carvedilol in the treatment of hypertension—a review of the clinical data base,” Scandinavian Cardiovascular Journal, Supplement, vol. 32, no. 47, pp. 67–80, 1998. View at Google Scholar · View at Scopus
  59. H. Xiaozhen, Z. Yun, Z. Mei, and S. Yu, “Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy,” Blood Pressure, vol. 19, no. 1, pp. 40–47, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. D. Levy, M. G. Larson, R. S. Vasan, W. B. Kannel, and K. K. L. Ho, “The progression from hypertension to congestive heart failure,” Journal of the American Medical Association, vol. 275, no. 20, pp. 1557–1562, 1996. View at Publisher · View at Google Scholar · View at Scopus
  61. A. K. Dhalla, M. F. Hill, and P. K. Singal, “Role of oxidative stress in transition of hypertrophy to heart failure,” Journal of the American College of Cardiology, vol. 28, no. 2, pp. 506–514, 1996. View at Publisher · View at Google Scholar · View at Scopus
  62. H. J. Dargie, “Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial,” Lancet, vol. 357, no. 9266, pp. 1385–1390, 2001. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Packer, M. R. Bristow, J. N. Cohn et al., “The effect of carvedilol on morbidity and mortality in patients with chronic heart failure,” New England Journal of Medicine, vol. 334, no. 21, pp. 1349–1355, 1996. View at Publisher · View at Google Scholar · View at PubMed
  64. G. L. Bakris, V. Fonseca, R. E. Katholi et al., “Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial,” Journal of the American Medical Association, vol. 292, no. 18, pp. 2227–2236, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. D. S. Siscovick, T. E. Raghunathan, B. M. Psaty et al., “Diuretic therapy for hypertension and the risk of primary cardiac arrest,” New England Journal of Medicine, vol. 330, no. 26, pp. 1852–1857, 1994. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. A. Bayes-Genis, J. Guindo, X. Vinolas et al., “Cardiac arrhythmias and left ventricular hypertrophy in systemic hypertension and their influences on prognosis,” American Journal of Cardiology, vol. 76, no. 13, pp. 54D–59D, 1995. View at Publisher · View at Google Scholar · View at Scopus
  67. W. T. Woods, R. E. Katholi, F. Urthaler, and T. N. James, “Electrophysiological effects of magnesium on cells in the canine sinus node and false tendon,” Circulation Research, vol. 44, no. 2, pp. 182–188, 1979. View at Google Scholar · View at Scopus
  68. V. K. Raman, Y. A. Lee, and K. Lindpaintner, “The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy,” American Journal of Cardiology, vol. 76, no. 13, pp. 18D–23D, 1995. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Epstein and G. Bakris, “Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy,” Archives of Internal Medicine, vol. 156, no. 17, pp. 1969–1978, 1996. View at Publisher · View at Google Scholar · View at Scopus
  70. B. Williams and P. S. Lacy, “Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate,” Journal of the American College of Cardiology, vol. 54, no. 8, pp. 705–713, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. C. Indolfi, E. Di Lorenzo, C. Perrino et al., “Hydroxymethylglutaryl coenzyme a reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation,” Circulation, vol. 106, no. 16, pp. 2118–2124, 2002. View at Publisher · View at Google Scholar · View at Scopus
  72. F. Simko, “Statins: a perspective for left ventricular hypertrophy treatment,” European Journal of Clinical Investigation, vol. 37, no. 9, pp. 681–691, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. R. E. Katholi, K. J. Rocha-Singh, N. J. Goswami, and P. A. Sobotka, “Renal nerves in the maintenance of hypertension: a potential therapeutic target,” Current Hypertension Reports, vol. 12, pp. 196–204, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. H. Krum, M. Schlaich, R. Whitbourn et al., “Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study,” The Lancet, vol. 373, no. 9671, pp. 1275–1281, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. M. P. Schlaich, P. A. Sobotka, H. Krum, E. Lambert, and M. D. Esler, “Renal sympathetic-nerve ablation for uncontrolled hypertension,” New England Journal of Medicine, vol. 361, no. 9, pp. 932–934, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus